DeepMed Research

Akeso

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: $5B

Website

Clinical Trials

A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Phase 3

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: AK117 in combination with AK112
Drug: Placebo in combination with Pembrolizumab

First Posted Date: 2024-09-19

Last Posted Date: 2024-11-14

Lead Sponsor: Akeso

Target Recruit Count: 510

Registration Number: NCT06601335

Locations: 🇨🇳
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China

AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer

Phase 3

Not yet recruiting

Conditions: Biliary Tract Cancer

Interventions: Drug: AK112, Gemcitabine, Cisplatin
Drug: Durvalumab, Gemcitabine, Cisplatin

First Posted Date: 2024-09-11

Last Posted Date: 2024-09-11

Lead Sponsor: Akeso

Target Recruit Count: 682

Registration Number: NCT06591520

Locations: 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, China
🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, China

A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma

Phase 1

Not yet recruiting

Conditions: Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

First Posted Date: 2024-09-06

Last Posted Date: 2024-09-06

Lead Sponsor: Akeso

Target Recruit Count: 294

Registration Number: NCT06586294

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hanzhou, Zhejiang, China

An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer

Phase 2

Recruiting

Conditions: Recurrent Ovarian Cancer

Interventions: Drug: AK112
Drug: AK104
Drug: Chemotherapy

First Posted Date: 2024-08-19

Last Posted Date: 2025-03-12

Lead Sponsor: Akeso

Target Recruit Count: 172

Registration Number: NCT06560112

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

A Phase Ib/II Study of AK112 (PD-1/VEGF Bispecific Antibody) in Combination Therapy for Patients With Advanced Hepatocellular Carcinoma (HCC).

Phase 1

Not yet recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: AK112
Drug: Sintilimab Injection
Drug: AK130
Drug: AK127
Drug: Bevacizumab biosimilar
Drug: Cadonilimab

First Posted Date: 2024-07-31

Last Posted Date: 2024-07-31

Lead Sponsor: Akeso

Target Recruit Count: 280

Registration Number: NCT06530251

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳
Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute,Shandong Cancer Hospital), Jinan, Shandong, China

A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia

Phase 1

Not yet recruiting

Conditions: ACUTE MYELOID LEUKEMIA; AML

Interventions: Drug: AK117
Drug: Azacitidine
Drug: Venetoclax
Other: Placebo

First Posted Date: 2024-04-29

Last Posted Date: 2024-04-29

Lead Sponsor: Akeso

Target Recruit Count: 180

Registration Number: NCT06387420

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic Dermatitis

Phase 3

Recruiting

Conditions: Atopic Dermatitis

Interventions: Drug: AK120

First Posted Date: 2024-04-25

Last Posted Date: 2024-04-25

Lead Sponsor: Akeso

Target Recruit Count: 420

Registration Number: NCT06383468

Locations: 🇨🇳
Beijing Friendship Hospital Capital Medical University, Beijing, Beijing, China
🇨🇳
Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

and more 56 locations

A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis

Phase 3

Recruiting

Conditions: Ankylosing Spondylitis

Interventions: Drug: AK111
Drug: Placebo+AK111

First Posted Date: 2024-04-22

Last Posted Date: 2024-04-22

Lead Sponsor: Akeso

Target Recruit Count: 510

Registration Number: NCT06378697

Locations: 🇨🇳
1027-Lanzhou University Second Hospital, Lanzhou, Gansu, China
🇨🇳
1005-Nanfang Hospital, Guangzhou, Guangdong, China
🇨🇳
1030-Jieyang People's Hospital, Jieyang, Guangdong, China

and more 51 locations

A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

Phase 3

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: AK104
Other: Placebo for AK104
Drug: Lenvatinib
Procedure: TACE
Other: Placebo for Lenvatinib

First Posted Date: 2024-04-17

Last Posted Date: 2025-03-12

Lead Sponsor: Akeso

Target Recruit Count: 469

Registration Number: NCT06371157

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳
Zhongda Hospital Southeast University, Nanjing, Jiangsu, China

and more 1 locations

A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

Phase 3

Recruiting

Conditions: Gastric and Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: cadonilimab
Drug: placebo
Drug: pulocimab
Drug: paclitaxel

First Posted Date: 2024-04-02

Last Posted Date: 2024-06-24

Lead Sponsor: Akeso

Target Recruit Count: 506

Registration Number: NCT06341335

Locations: 🇨🇳
Peking University Cancer Hospital & Institute, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy